secwatch.observer — SEC 8-K summary
======================================

Issuer:     Artiva Biotherapeutics, Inc. (ARTV)
CIK:        0001817241
Form:       8-K
Filed at:   2026-08-06T20:09:11+00:00
Accession:  0001193125-26-337986
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Artiva Q2 net loss $25M; cash $349.4M; RMAT granted; Phase 3 RA trial to start H2 2026
--------------------------------------------------------------------------------

- Cash, cash equivalents and investments of $349.4M as of June 30, 2026, expected to fund operations into 2029.
- Net loss of $25.0M for Q2 2026 vs $21.3M for Q2 2025; R&D expenses $21.9M vs $17.9M.
- FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to AlloNK plus rituximab for refractory RA.
- Phase 3 randomized controlled trial of AlloNK plus rituximab vs rituximab alone in ~150 RA patients to start H2 2026.
- Completed ~$300M underwritten offering in May 2026; appointed Diego Miralles, M.D., as president and head of R&D.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817241/000119312526337986/0001193125-26-337986-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817241/000119312526337986/artv-20260806.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-337986

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer